Cost-minimization study comparing Simulect versus Thymoglobulin in renal transplant induction

Transplantation Proceedings

Volumn 33, Issue 7-8, 2001, Pages 3197-3198

  Lilliu, H ^a   Brun, C ^b   Le Pen, C ^c   Buchler M ^d   Al Najjar, A ^d   Reigneau, O ^b   Lebranchu, Y ^d  

^a CLP Santé H L   (France)

^b NOVARTIS PHARMA K K   (Japan)

^c UNIVERSITÉ PARIS DAUPHINE   (France)

^d CHU BRETONNEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; CYTOMEGALIC INCLUSION BODY DISEASE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC EVALUATION; HEALTH CARE COST; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; COST CONTROL; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FRANCE; HOSPITALIZATION; HUMANS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECOMBINANT FUSION PROTEINS;

EID: 0035674760     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(01)02360-0     Document Type: Article

References (0)